資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/32245
|
| 標題: | Prolonged Mechanical Ventilation Assistance Interacts Synergistically with Carbapenem for Clostridium difficile Infection in Critically Ill Patients |
| 作者: | Chiang, Shyh-Ren
Lai, Chih-Cheng
Ho, Chung-Han
Chen, Chin-Ming
Chao, Chien-Ming
Wang, Jhi-Joung
Cheng, Kuo-Chen |
| 貢獻者: | Chi Mei Med Ctr, Dept Internal Med
Chia Nan Univ Pharm & Sci, Dept Gen Educ
Chi Mei Med Ctr, Dept Intens Care Med
Chi Mei Med Ctr, Dept Med Res
Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm
Chi Mei Med Ctr, Dept Intens Care Med
Chia Nan Univ Pharm & Sci, Dept Recreat
Chia Nan Univ Pharm & Sci, Dept Healthcare Management
Chung Hwa Univ Med Technol, Dept Safety Hlth & Environm Engn |
| 關鍵字: | mechanical ventilation
interact synergistically
carbapenem
Clostridium difficile infection
critically ill patients |
| 日期: | 2018-08 |
| 上傳時間: | 2019-11-15 15:46:38 (UTC+8) |
| 出版者: | MDPI |
| 摘要: | Objectives: Interactions between mechanical ventilation (MV) and carbapenem interventions were investigated for the risk of Clostridium difficile infection (CDI) in critically ill patients undergoing concurrent carbapenem therapy. Methods: Taiwan's National Intensive Care Unit Database (NICUD) was used in this analytical, observational, and retrospective study. We analyzed 267,871 intubated patients in subgroups based on the duration of MV support: 7-14 days (n = 97,525), 15-21 days (n = 52,068), 22-28 days (n = 35,264), and 29-60 days (n = 70,021). The primary outcome was CDI. Results: Age (>75 years old), prolonged MV assistance (>21 days), carbapenem therapy (>15 days), and high comorbidity scores were identified as independent risk factors for developing CDI. CDI risk increased with longer MV support. The highest rate of CDI was in the MV 29-60 days subgroup (adjusted hazard ratio (AHR) = 2.85; 95% confidence interval (CI) = 1.46-5.58; p < 0.02). Moreover, higher CDI rates correlated with the interaction between MV and carbapenem interventions; these CDI risks were increased in the MV 15-21 days (AHR = 2.58; 95% CI = 1.12-5.91) and MV 29-60 days (AHR = 4.63; 95% CI = 1.14-10.03) subgroups than in the non-MV and non-carbapenem subgroups. Conclusions: Both MV support and carbapenem interventions significantly increase the risk that critically ill patients will develop CDI. Moreover, prolonged MV support and carbapenem therapy synergistically induce CDI. These findings provide new insights into the role of MV support in the development of CDI. |
| link: | http://dx.doi.org/10.3390/jcm7080224 |
| 關聯: | Journal of Clinical Medicine, v.7, n.8, 224 |
| 顯示於類別: | [通識教育中心] 期刊論文
[醫務管理系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| 10.3390-jcm7080224.pdf | | 910Kb | Adobe PDF | 277 | 檢視/開啟 | | index.html | | 0Kb | HTML | 1122 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
